Phase II Study of Vorinostat (SAHA, Zolinza) and Bortezomib (PS341, Velcade) as Third-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer.

Trial Profile

Phase II Study of Vorinostat (SAHA, Zolinza) and Bortezomib (PS341, Velcade) as Third-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2016

At a glance

  • Drugs Bortezomib (Primary) ; Vorinostat (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Mar 2013 Planned end date changed from 1 Dec 2011 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 02 Dec 2011 Planned End Date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 26 May 2010 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top